文献速递甲状腺疾病

3,3',5-三碘甲状腺乙酸转运体

3,3',5-Triiodothyroacetic Acid Transporters.
PubMed 文献 · Thyroid · 2024-07-03

本研究筛选表达于人血脑屏障和/或脑-脑脊液屏障的候选转运体及已知甲状腺激素转运体,在COS-1细胞中评估1 nM 3,3',5-三碘甲状腺乙酸(TRIAC)的胞内蓄积。结果显示SLCO1B1和SLC22A8(在DPBS/0.1%葡萄糖和DMEM中)以及SLC10A1、SLC22A6和SLC22A24(在DMEM中)在牛血清白蛋白存在下可显著转运TRIAC,其斑马鱼和小鼠直系同源物同样促进TRIAC胞内蓄积。

要点

  • 共筛选59个质膜转运体,18个在无牛血清白蛋白条件下促进TRIAC显著胞内蓄积。
  • 牛血清白蛋白存在下,SLCO1B1和SLC22A8(DPBS/0.1%葡萄糖和DMEM)及SLC10A1、SLC22A6、SLC22A24(DMEM)转运显著。
  • 小鼠Slc22a8 mRNA在出生后早期脑毛细血管内皮细胞和脉络丛上皮细胞表达最高,P120时降低。

核心结论

  • 人SLC10A1、SLCO1B1、SLC22A6、SLC22A8和SLC22A24及其小鼠和斑马鱼直系同源物是高效的TRIAC转运体。
  • 这些发现有助于理解MCT8缺陷患者及其动物模型中的TRIAC治疗。

研究设计与样本

  • 研究在COS-1细胞中表达候选转运体,用细胞表面生物素化测定质膜表达,评估1 nM TRIAC在DPBS/0.1%葡萄糖或DMEM(含或不含0.1%牛血清白蛋白)中的胞内蓄积。
  • 共筛选59个质膜转运体:40个基于在人血脑屏障和/或脑-脑脊液屏障表达且以小有机分子为底物,19个为已知甲状腺激素转运体。
  • 用荧光原位杂交检测野生型和Mct8/Oatp1c1敲除小鼠出生后第12、21和120天脑切片中Slc22a8的表达。

主要发现

  • 筛选显示18个转运体在无牛血清白蛋白的DPBS/0.1%葡萄糖或DMEM中促进TRIAC显著胞内蓄积。
  • 牛血清白蛋白存在下,SLCO1B1和SLC22A8在DPBS/0.1%葡萄糖和DMEM中、SLC10A1、SLC22A6和SLC22A24在DMEM中观察到显著转运。
  • 这些转运体的斑马鱼和小鼠直系同源物同样促进TRIAC胞内蓄积。
  • 小鼠脑毛细血管内皮细胞和脉络丛上皮细胞中Slc22a8 mRNA在出生后早期时间点表达最高,P120时降低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction: Thyroid hormone transporters are essential for thyroid hormones to enter target cells. Monocarboxylate transporter (MCT) 8 is a key transporter and is expressed at the blood-brain barrier (BBB), in neural cells and many other tissues. Patients with MCT8 deficiency have severe neurodevelopmental delays because of cerebral hypothyroidism and chronic sequelae of peripheral thyrotoxicosis. The T3 analog 3,3',5-triiodothyroacetic acid (TRIAC) rescued neurodevelopmental features in animal models mimicking MCT8 deficiency and improved key metabolic features in patients with MCT8 deficiency. However, the identity of the transporter(s) that facilitate TRIAC transport are unknown. Here, we screened candidate transporters that are expressed at the human BBB and/or brain-cerebrospinal fluid barrier and known thyroid hormone transporters for TRIAC transport. Materials and Methods: Plasma membrane expression was determined by cell surface biotinylation assays. Intracellular accumulation of 1 nM TRIAC was assessed in COS-1 cells expressing candidate transporters in Dulbecco's phosphate-buffered saline (DPBS)/0.1% glucose or Dulbecco's modified Eagle's medium (DMEM) with or without 0.1% bovine serum albumin (BSA). Expression of Slc22a8 was determined by fluorescent in situ hybridization in brain sections from wild-type and Mct8/Oatp1c1 knockout mice at postnatal days 12, 21, and 120. Results: In total, 59 plasma membrane transporters were selected for screening of TRIAC accumulation (n = 40 based on expression at the human BBB and/or brain-cerebrospinal fluid barrier and having small organic molecules as substrates; n = 19 known thyroid hormone transporters). Screening of the selected transporter panel showed that 18 transporters facilitated significant intracellular accumulation of TRIAC in DPBS/0.1% glucose or DMEM in the absence of BSA. In the presence of BSA, substantial transport was noted for SLCO1B1 and SLC22A8 (in DPBS/0.1% glucose and DMEM) and SLC10A1, SLC22A6, and SLC22A24 (in DMEM). The zebrafish and mouse orthologs of these transporters similarly facilitated intracellular accumulation of TRIAC. Highest Slc22a8 mRNA expression was detected in mouse brain capillary endothelial cells and choroid plexus epithelial cells at early postnatal time points, but was reduced at P120. Conclusions: Human SLC10A1, SLCO1B1, SLC22A6, SLC22A8, and SLC22A24 as well as their mouse and zebrafish orthologs are efficient TRIAC transporters. These findings contribute to the understanding of TRIAC treatment in patients with MCT8 deficiency and animal models thereof.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Chen Z, Yildiz S, Markova B, et al. 3,3',5-Triiodothyroacetic Acid Transporters. Thyroid. 2024. PMID: 38836423. doi:10.1089/thy.2023.0467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。